Breast Cancer News and Research

Latest Breast Cancer News and Research

ACS recommends annual MRI screening in women with family history of breast cancer

Women with a personal history of breast cancer should consider annual screening with MRI in addition to mammography, according to a study presented today at the annual meeting of the Radiological Society of North America (RSNA).

29 Nov 2010

GE Healthcare highlights technologies to support healthymagination strategy at RSNA 2010

Increasing access. Improving quality and efficiency. Lowering costs. When GE launched its healthymagination initiative last year, these were the long-term goals and at RSNA 2010, GE Healthcare will highlight a variety of technologies developed to support this strategy and help improve patient care worldwide.

28 Nov 2010

IMPAX for breast imaging eliminates limitations of modality-specific review stations at Cleveland Clinic Breast Center

IMPAX for Breast Imaging from Agfa HealthCare, a leading provider of diagnostic imaging and healthcare IT solutions has effectively improved workflow at Cleveland Clinic Breast Center by eliminating digital mammography modality-specific review stations and providing instead a single integrated workflow with true multi-modality capability, according to a white paper released today by Agfa HealthCare.

28 Nov 2010

SuperSonic signs distribution agreement with Hologic to develop breast ultrasound market in the U.S

SuperSonic Imagine, the innovative producer of ultrasound equipment, announced today that it has signed an exclusive distribution agreement with Hologic, Inc. to develop the breast ultrasound market in the United States.

From Hologic, Inc. 26 Nov 2010

Personalized oncology requires new paradigm for drug development, experts say

Millions of cancer patients worldwide may soon be able to receive more effective, personalized treatments for their disease thanks to developments in the understanding of cancer biology, experts will say at the Cancer Biology for Clinicians Symposium organized by the European Society for Medical Oncology (ESMO) in Nice this week.

25 Nov 2010

Researchers explain molecular mechanism that induces HER2+ tumours to ignore cell signals

About 30% of breast cancer patients have tumours that show rapid growth and invasion through the body. A common denominator in all of these cases is the presence of a large number of Her2 proteins in tumour cellular membranes. Consequently, these aggressive tumours are referred to as HER2+. Scientists working in the Metastasis Laboratory (MetLab) at IRB Barcelona headed by ICREA researcher Roger Gomis, have described the molecular mechanism that induces HER2+ tumours to ignore the signals that protect cells from excessive growth.

25 Nov 2010

LCA calls for public discussion on guidance for lung cancer screening

Today, Lung Cancer Alliance (LCA) President & CEO Laurie Fenton-Ambrose said the recent breakthrough on CT screening for lung cancer is an extraordinary development in the battle against lung cancer and reiterated her call for an open and balanced public discussion on guidance for those at high risk who may be considering a scan.

25 Nov 2010

New NIVI tissue-imaging technique can accurately detect cancer cells

The long, anxious wait for biopsy results could soon be over, thanks to a tissue-imaging technique developed at the University of Illinois.

25 Nov 2010

Cancers detected late leading to unnecessary deaths: Report

A new report released Wednesday by the U.S. Centers for Disease Control and Prevention (CDC) says that in spite of the widely available screening tests many cancers are not diagnosed until the disease is well-advanced and, therefore, less treatable and more fatal. The report says that half of colorectal cancers and cervical cancers and one-third of breast cancers in the United States are detected at a late stage.

24 Nov 2010

A new treatment landscape for triple-negative breast cancer

A concerted R&D effort directed at triple-negative breast cancer patients promises new treatment options in the near future, according to latest research from independent market analyst, Datamonitor.

24 Nov 2010

Blocking miR-375 microRNA in ERalha-positive breast cancer cells slows down cancer cell growth

Two thirds of breast cancers are ERalpha-positive, i.e., many estrogen receptors of the ERalpha- type are found in their cells. "These molecules can interact with the estrogen hormone and, thus, even lead to cancer," explains Dr. Joerg Hoheisel; molecular biologist at DKFZ. "The connection between the levels of the estrogen receptor alpha and the occurrence of breast cancer has been known for some time now.

24 Nov 2010

Provectus reports progress in PV-10 program for metastatic melanoma

Provectus Pharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, reports continued progress in its compassionate use program for PV-10. The program currently has enrolled more than 40 patients, ten of whom are expanded access patients from the company's Phase 2 trial of PV-10 for metastatic melanoma, as well as more than 30 new patients.

24 Nov 2010

IDSI submits Premarket Notification for CTLM breast imaging device to FDA

Imaging Diagnostic Systems, Inc., a pioneer in laser breast imaging, announced today that a Premarket Notification 510(k) was submitted on Monday, November 22, 2010, to the United States Food and Drug Administration (FDA). With this submission, the company moves forward in the process of seeking marketing clearance for its innovative breast imaging device, the CTLM system.

23 Nov 2010

Disrupting estrogen pathway can halt expansion of breast cancer stem cells: Research

Breast cancer stem cells (CSCs), the aggressive cells thought to be resistant to current anti-cancer therapies and which promote metastasis, are stimulated by estrogen via a pathway that mirrors normal stem cell development.

23 Nov 2010

Hologic announces receipt of FDA approvable letter for Selenia Dimensions 3-D digital mammography system

Hologic, Inc., a leading developer, manufacturer and supplier of premium diagnostics products, medical imaging systems and surgical products dedicated to serving the healthcare needs of women, announced today that Hologic has received an approvable letter from the U.S. Food and Drug Administration (FDA) for the Selenia Dimensions three-dimensional (3-D) digital mammography tomosynthesis system.

From Hologic, Inc. 23 Nov 2010

DiaGenic ASA announces subsequent offering of 60,000,000 shares

Reference is made to the stock exchange notice dated 3 November 2010 and the prospectus dated 2 November 2010 regarding a subsequent offering of up to 60,000,000 offer shares in DiaGenic ASA each with a nominal value of NOK 0.05, at a subscription price of NOK 0.50 per share with subscription rights for shareholders of the Company as of 6 October 2010, except shareholders who were allocated shares in the private placement completed on 6 October 2010.

23 Nov 2010

$S*BIO begins SB1317 Phase 1 clinical trial in patients with advanced/refractory hematologic malignancies$

S*BIO begins SB1317 Phase 1 clinical trial in patients with advanced/refractory hematologic malignancies

S*BIO Pte Ltd today announced that a fourth novel, potential best-in-class compound discovered and developed by S*BIO has entered a Phase 1 clinical trial. The initiation of the study for S*BIO's oral multi-kinase inhibitor, SB1317 or TG02, in patients with advanced/refractory hematologic malignancies has triggered a payment from S*BIO's development and commercialization partner for the program, Tragara Pharmaceuticals.

22 Nov 2010

IsoRay to sell $2.25 million in common stock

IsoRay Inc. has entered a securities purchase agreement with an investor to sell $2.25 million in common stock with the potential of $2,075,000 additional funding through two subsequent short term warrant tranches of 90 days and 180 days assuming an average exercise price of $1.40 and that all Series A and B warrants are exercised. Additional funding will occur if Series C or D warrants are exercised.

22 Nov 2010

Phase 3 study of VEGF Trap-Eye regimen meets primary endpoint in patients with wet AMD

Regeneron Pharmaceuticals, Inc. and Bayer HealthCare announced that in two parallel Phase 3 studies in patients with the neovascular form of age-related macular degeneration (wet AMD), all regimens of VEGF Trap-Eye (aflibercept ophthalmic solution), including VEGF Trap-Eye dosed every two months, successfully met the primary endpoint compared to the current standard of care, ranibizumab dosed every month.

22 Nov 2010

New I-SPY 2 study to evaluate effectiveness of medical treatment for breast cancer

A clinical trial that aims to speed up the study of new treatments for certain subtypes of breast cancer now has a designated study site at the Diane O'Connor Thompson Breast Center at the University of Colorado Hospital.

20 Nov 2010

Breast Cancer News and Research

Latest Breast Cancer News and Research

ACS recommends annual MRI screening in women with family history of breast cancer

GE Healthcare highlights technologies to support healthymagination strategy at RSNA 2010

IMPAX for breast imaging eliminates limitations of modality-specific review stations at Cleveland Clinic Breast Center

SuperSonic signs distribution agreement with Hologic to develop breast ultrasound market in the U.S

Personalized oncology requires new paradigm for drug development, experts say

Researchers explain molecular mechanism that induces HER2+ tumours to ignore cell signals

LCA calls for public discussion on guidance for lung cancer screening

New NIVI tissue-imaging technique can accurately detect cancer cells

Cancers detected late leading to unnecessary deaths: Report

A new treatment landscape for triple-negative breast cancer

Blocking miR-375 microRNA in ERalha-positive breast cancer cells slows down cancer cell growth

Provectus reports progress in PV-10 program for metastatic melanoma

IDSI submits Premarket Notification for CTLM breast imaging device to FDA

Disrupting estrogen pathway can halt expansion of breast cancer stem cells: Research

Hologic announces receipt of FDA approvable letter for Selenia Dimensions 3-D digital mammography system

DiaGenic ASA announces subsequent offering of 60,000,000 shares

S*BIO begins SB1317 Phase 1 clinical trial in patients with advanced/refractory hematologic malignancies

IsoRay to sell $2.25 million in common stock

Phase 3 study of VEGF Trap-Eye regimen meets primary endpoint in patients with wet AMD

New I-SPY 2 study to evaluate effectiveness of medical treatment for breast cancer

Unlocking live single-cell functional insights

Fluidics in Modern Healthcare & Medical Device Innovation

How microRNA is transforming science: From discovery to diagnostics

Breast Cancer News and Research

Latest Breast Cancer News and Research

Unlocking live single-cell functional insights

Fluidics in Modern Healthcare & Medical Device Innovation

How microRNA is transforming science: From discovery to diagnostics

Newsletters you may be interested in